Connect with us

Health

Canada extends COVID-19 border measures until Sept. 30, including ArriveCan app

Published

 on

OTTAWA — The federal government will extend current COVID-19 public health measures for travellers entering Canada, including the use of the ArriveCan app, until at least Sept. 30.

In a release Wednesday, the Public Health Agency of Canada also said it will continue the pause of mandatory random testing for fully vaccinated travellers at all airports until mid-July.

It first announced the pause on June 11 and said in the release that it’s allowing airports to focus on streamlining their operations.

The public health agency said it’s moving forward with plans to relocate COVID-19 testing for air travellers outside of airports to select test provider stores, pharmacies or by virtual appointment.

Mandatory random testing is to continue at land border points of entry with no changes.

The release added that travellers who are not fully vaccinated and don’t have a valid exemption must continue to test on Day 1 and Day 8 of their 14-day quarantine.

“As we move into the next phase of our COVID-19 response, it is important to remember that the pandemic is not over. We must continue to do all that we can to keep ourselves and others safe from the virus,” said Health Minister Jean-Yves Duclos in a statement.

He also urged people to remain up to date with the recommended vaccinations to ensure they are adequately protected against infection, transmission and severe complications.

“As we have said all along, Canada’s border measures will remain flexible and adaptable, guided by science and prudence.”

All travellers will have to continue to use the ArriveCan app or website to provide their travel information within 72 hours before their arrival in Canada or before boarding a cruise ship destined for the country. The government said 95 per cent of land and air travellers are using the app and it’s taking steps to enhance compliance.

The government also said moving testing outside of airports will allow Canada to adjust to increased traveller volumes while still being able to monitor and quickly respond to new variants of concern or changes to the epidemiological situation.

It said border testing has been essential in helping Canada slow the spread of the virus, as data from the tests are used to understand the current level and trends of importation of COVID-19 into the country.

The testing program also allows for detection and identification of new COVID-19 variants of concern, it said.

Tourism groups and border-community mayors and MPs have called on the government to ease restrictions and scrap the ArriveCan app, saying the measures are limiting cross-border travel.

Transport Minister Randy Boissonnault said the government is deeply invested in growing Canada’s visitor economy.

“From our reputation as a safe travel destination to our world-class attractions and wide-open spaces, Canada has it all and we are ready to welcome back domestic and international tourists, while prioritizing their safety and well-being.”

This report by The Canadian Press was first published June 29, 2022.

 

The Canadian Press

Health

Saskatchewan warns of elevated monkeypox risk through 'anonymous sexual contact' – Niagara Falls Review

Published

 on


REGINA – Saskatchewan’s health-care delivery agency is warning there’s an elevated risk of acquiring monkeypox through anonymous sexual contact, and it’s expanding vaccine eligibility to adults 18 years and older who are close contacts or deemed higher risk for exposure.

The chief medical officer of health told reporters during a news conference Saturday that monkeypox cases in the province remain low — so far only three have been confirmed.

But Dr. Saqib Shahab says if people meet the risk criteria and have concerns, they should call the province’s 811 HealthLine for advice on testing, as well as on obtaining a pre-exposure vaccination.

The Saskatchewan Health Authority issued a news release saying the warning about catching monkeypox through anonymous sexual contact is due to recent known cases.

It adds information reported to public health, related to travel into and out of province, has prompted the alert.

Shahab says Saskatchewan wants to do everything it can to prevent a surge in cases.

“I think with travel interactions throughout Canada in the summer, I think this risk was bound to change for us in Saskatchewan and that’s why we are now really opening up the vaccine, not just for post-exposure prophylaxis, but for pre-exposure as well, for the very targeted group that we’ve identified,” Shahab said at the news conference.

“Obviously we don’t want over-testing happening, but in the right context, I think it’s important to seek testing, exactly for the reason that we don’t want to miss cases.”

So far, he said there have been no cases in Saskatchewan where a history of exposure hasn’t been identified. Additional vaccine doses have been ordered now that the province has expanded eligibility, he noted.

Monkeypox, which comes from the same family of viruses that cause smallpox, has been endemic in parts of central and west Africa for decades and was not known to trigger large outbreaks beyond the continent until May.

It causes fever, headache, swollen lymph nodes and lethargy, followed by the development of a rash over a person’s body. It spreads through close, personal, often skin-to-skin contact, touching bodily fluids or lesions of a person who is sick with the disease or exposure to contaminated objects such as bed linens or clothing.

The Public Health Agency of Canada says the majority of domestic cases are among men who reported intimate sexual contact with other men. Having multiple sexual partners may increase one’s overall risk, but the agency says the risk of exposure is not exclusive to any group or setting.

The number of Canadian monkeypox cases surpassed 1,000 just this week, though there are early signs the virus may now be spreading at a slower rate.

This report by The Canadian Press was first published Aug. 13, 2022.

Adblock test (Why?)



Source link

Continue Reading

Health

Sask Health alerts public of elevated risk of acquiring monkeypox – Global News

Published

 on


The Saskatchewan Health Authority is alerting the public of an elevated risk of acquiring monkeypox through anonymous sexual contact.

Recent known cases have been associated with this form of transmission, and information reported to public health related to travel in and out of the province has prompted the alert.

Read more:

18+ eligible for 2nd COVID-19 vaccine booster in Saskatchewan on Monday

“We’ve have been following the global monkeypox outbreak very closely for the last five months now,” said Dr. Saqib Shahab, the Chief Medical Health Officer for Saskatchewan.

“We think now there is a higher risk that we may see ongoing transmission in Saskatchewan.”

There are three confirmed cases of monkeypox in the province. Shahab said the cases so far have been from people exposed outside of Saskatchewan, however there are now people who have been exposed inside the province.

“We have evidence of exposures happening in Saskatchewan,” Shahab said. “In many cases through anonymous sexual contacts. This is very similar to what has been seen in other provinces in Canada and internationally.”

Monkeypox is a rare viral illness that causes fever, headache, swollen lymph nodes and lethargy, followed by the development of a rash over a person’s body. Monkeypox does not spread easily from person to person. It is spread through:

  • Close, personal, often skin-to-skin contact.
  • Touching bodily fluids or lesions of a person who is sick with the disease.
  • Exposure to contaminated objects such as bed linens or clothing.

Anyone who believes they have been exposed to monkeypox can contact Healthline 811 to determine if they are considered at risk or eligible for a vaccine.

Read more:

Saskatchewan child care fees going down 70% starting Sept. 1

Eligibility for the monkeypox vaccine has been expanded to adults 18 years and older who are close contacts or deemed higher risk for exposure. Referrals are available through 811.

“With travel, with interactions in summer, this risk was bound to change,” Shahab said. “Now we are really opening up the vaccine for not just post-exposure… but for pre-exposure as well with the groups we have identified.”

The province has ordered additional vaccines to help with both pre-exposure and post-exposure, and plan to order even more if the demand increases.

Shahab hopes with the increase in vaccines and awareness of the symptoms, transmission can stay low in the province.

“We are really hopeful both in Saskatchewan and Canada that through all these measures of raising awareness so people are aware of symptoms and the can isolate, seek testing and now seek pre exposure vaccines, we really hope we can control this outbreak,” he said.

If you have recently been in contact with an individual suspected or confirmed with monkeypox and develop fever or other symptoms of illness, you should call HealthLine 811 or consult a health-care provider immediately.


Click to play video: 'About 50% of monkeypox vaccine supply used, Canada passes 1,000 cases: Tam'



4:16
About 50% of monkeypox vaccine supply used, Canada passes 1,000 cases: Tam


About 50% of monkeypox vaccine supply used, Canada passes 1,000 cases: Tam

© 2022 Global News, a division of Corus Entertainment Inc.

Adblock test (Why?)



Source link

Continue Reading

Health

Worse Vascular Outcomes Found in Patients With Asthma – AJMC.com Managed Markets Network

Published

 on


Patients with symptoms of asthma, regardless of physiological confirmation, experienced worse vascular outcomes and greater cardiovascular risk, which may be due to short-acting beta agonist (SABA) use, according to the results of a recent study.

Individuals with a clinical history of asthma had lower endothelial function than healthy controls, regardless of whether participants had physiological confirmation of the disease.

Study results, which were published in Respiratory Medicine, also showed that that participants with asthma who regularly used short-acting beta agonist (SABA) medications had increased arterial stiffness than those who did not use SABA.

Researchers aimed to compare markers of cardiovascular risk, specifically endothelial function, arterial stiffness, and systemic inflammation, among those with confirmed asthma, unconfirmed asthma, and healthy controls. Researchers also aimed to investigate the effect of SABA use on these vascular outcomes.

This cross-sectional study included 26 patients with confirmed asthma, 15 patients with unconfirmed asthma, and 26 healthy controls all recruited from the Edmonton, Canada metropolitan area. All participants in the study were aged between 18 to 45 years and current nonsmokers.

Participants completed a pulmonary function test and evaluation for asthma. Physiological evidence of asthma was defined as a clinical history of symptoms such as recurrent wheezing, cough, and/or chest tightness. Physiological evidence also includes a reversibility in forced expiratory volume in 1 second (FEV1) of ≥12% and 200mL, a ≥20% reduction in FEV1 after a methacholine challenge, or a ≥10% reduction in FEV1 after an exercise challenge.

Participants were labeled with confirmed asthma if they had a clinical history and physiological evidence of asthma. Those labelled with unconfirmed asthma had a clinical history but no physiological evidence of asthma. Healthy controls had no evidence of asthma. Researchers compared endothelial function, arterial stiffness, and systemic inflammation between these three groups of participants.

Researchers assessed participants’ endothelial function as flow-mediated dilation (FMD) after 5 minutes of supra-systolic forearm occlusion distal to the imaging site. A 1% decreased in FMD correlates with a 7% increase in cardiovascular risk.

Participants’ arterial stiffness was assessed using pulse wave velocity (PWV). PWV was measured between the carotid and radial artery. A 1 m/s increased in PWV corresponds to about a 16% increase in cardiovascular risk.

Systematic inflammation was assessed by C-reactive protein (CRP) levels in serum after venous blood was collected from the participants. CRP levels have been linked with cardiovascular risk, even for those without underlying cardiovascular morbidity.

Endothelial function was significantly lower in both confirmed and unconfirmed asthma groups than compared to healthy controls. There was no significant difference in FMD between the confirmed and unconfirmed asthma groups.

There was no significant difference found in arterial stiffness and systemic inflammation among both asthma groups and the controls.

Participants with bot confirmed and unconfirmed asthma were grouped together and then split based on SABA use. SABA was used by 19 participants and not used by 22 participants in the last year. There was no significant difference between in endothelial function and systemic inflammation between these two groups. However, SABA users had a significantly higher arterial stiffness by an average of 1.5 m/s than those not using SABA.

Limitations of this study include the small sample size and the inability to account for seasonal fluctuations in asthma symptoms due to the cross-sectional design. Also, this study did not adjust for other variables that can impact vascular outcomes.

Reduced vascular function was seen in participants with asthma regardless of physiological confirmation of asthma, suggesting that the link between asthma and cardiovascular risk may be due to factors other than asthma pathophysiology and perhaps due to asthma symptomatology, the researchers noted. The researchers also noted that this study highlights the need for proper asthma management to avoid inappropriate SABA use in patients with unconfirmed physiological asthma.

Reference

Henry SL, Moore LE, Brotto AR, Rowland S, Fuhr D, Stickland MK. Systemic vascular health is comprised in both confirmed and unconfirmed asthma. Respir Med. 2022;200. doi:10.1016/j.rmed.2022.106932

Adblock test (Why?)



Source link

Continue Reading

Trending